Literature DB >> 21270690

Analgesic effects of prostaglandin E2 receptor subtype EP1 receptor antagonist: experimental study of application of nucleus pulposus.

Miho Sekiguchi1, Kenichi Otoshi, Shin-ichi Kikuchi, Shin-ichi Konno.   

Abstract

STUDY
DESIGN: The effect of an EP1 receptor antagonist on pain-related behavior induced by nucleus pulposus (NP) applied to the dorsal root ganglion (DRG) in rats was investigated.
OBJECTIVE: We investigated pain-related behavior, the amount of prostaglandin E2 (PGE2), and neural damage to the DRG after application of NP to the DRG after administration of an EP1 receptor antagonist. SUMMARY OF BACKGROUND DATA: PGE2 induces mechanical allodynia and hyperalgesia, which are mediated by PGE2 receptors. EP1 is one of the PGE2 receptor subtypes. An EP1 antagonist reduces hyperalgesia, allodynia, and c-fos expression in the rat chronic nerve constriction model.
METHODS: Sprague-Dawley rats (n = 103) were used. Animals receiving NP were divided into three experimental groups (n = 12 in each group): saline, high-dose (5 mg/kg) EP1 receptor antagonist (RA), and low-dose (2.5 mg/kg) EP1-RA (orally once daily for 5 days). Animals in the sham group did not receive NP. Von Frey tests were used for pain-behavior testing. The amount of PGE2 in DRG and the number of activating transcription factor-3 (ATF3) immunoreactive positive cells were compared among groups.
RESULTS: The mechanical thresholds in the three groups decreased 7 days after surgery (just before treatment). The threshold in both the high- and low-dose EP1-RA groups increased at 11 days (5 days after treatment) and continued for 14 days. The thresholds in both the low- and high-dose EP1-RA groups increased significantly compared with the saline group (P < 0.05). The amount of PGE2 was significantly increased in the NP group compared with the sham and naïve animals after application of NP. ATF3 expression was increased by NP but was not increased after administration of the EP1-RA.
CONCLUSION: An EP1 receptor antagonist improves pain-related behavior in the rat model and might be a potential agent to improve pain-related behavior in patients with lumbar disc herniation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270690     DOI: 10.1097/BRS.0b013e3181fa1fca

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  6 in total

1.  The effect of selective serotonin reuptake inhibitor (SSRI) on pain-related behavior in a rat model of neuropathic pain.

Authors:  Hiroharu Saito; Jun Wakai; Miho Sekiguchi; Shinichi Kikuchi; Shinichi Konno
Journal:  Eur Spine J       Date:  2014-06-05       Impact factor: 3.134

2.  The effect of serotonin-noradrenaline reuptake inhibitor duloxetine on the intervertebral disk-related radiculopathy in rats.

Authors:  Junichi Handa; Miho Sekiguchi; Olga Krupkova; Shin-Ichi Konno
Journal:  Eur Spine J       Date:  2015-09-22       Impact factor: 3.134

3.  The effect of repeated restraint stress in pain-related behavior induced by nucleus pulposus applied on the nerve root in rats.

Authors:  Kazuhide Uesugi; Miho Sekiguchi; Shin-ichi Kikuchi; Shin-ichi Konno
Journal:  Eur Spine J       Date:  2011-06-23       Impact factor: 3.134

4.  The Effect of GCSB-5 a New Herbal Medicine on Changes in Pain Behavior and Neuroglial Activation in a Rat Model of Lumbar Disc Herniation.

Authors:  Hee Kyung Cho; So-Yeon Kim; Mi Jung Choi; Seung Ok Baek; Sang Gyu Kwak; Sang Ho Ahn
Journal:  J Korean Neurosurg Soc       Date:  2016-02-29

5.  Measurement of mechanical withdrawal thresholds and gait analysis using the CatWalk method in a nucleus pulposus-applied rodent model.

Authors:  Takuya Kameda; Yoichi Kaneuchi; Miho Sekiguchi; Shin-Ichi Konno
Journal:  J Exp Orthop       Date:  2017-09-29

Review 6.  Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception.

Authors:  Yongwoo Jang; Minseok Kim; Sun Wook Hwang
Journal:  J Neuroinflammation       Date:  2020-01-22       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.